There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

OBJECTIVE. This educational review focuses on the staging and radiologic evaluation of
renal cell carcinoma. It includes discussion of the epidemiology, pathology, and therapeutic …

Papillary renal cell carcinoma (pRCC) is the second most common type of renal cell
carcinoma (RCC). pRCC has unique imaging and clinical features that may allow …

Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …

Purpose To report updated analyses of the phase III CheckMate 214 trial with extended
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab …

Purpose: Clinical features characteristic of small-cell prostate carcinoma
(SCPC),“anaplastic,” often emerge during the progression of prostate cancer. We sought to …

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …